Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
The MoU proposed investments in hospitals, pharmacies and laboratories in the state
Arizona-based, leading medical devices company, Confluent Medical Technologies, will be establishing a pilot manufacturing facility in Hyderabad.
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Additional data across neurological disorders, including Alzheimer’s disease, help advance the scientific understanding of these conditions and the potential impact of early treatment
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
The Centre will be instrumental in streamlining vaccination resources and facilitate equitable access to safe and efficacious COVID-19 vaccines
Moving well beyond the traditional approach of testing a vaccine’s collective response in large populations, this precision approach can identify how an individual’s own immune system responds to a vaccine, offering an unprecedented opportunity to measure vaccine safety and effectiveness
Sputnik Light is the first component of Sputnik V
Subscribe To Our Newsletter & Stay Updated
